Note 5. Net Loss Per Share
Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to re purchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three and six months ended December 31, 2021 and 2020. Diluted net loss per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period.
The following table presents the calculation of net loss used to calculate basic loss and diluted loss per share (in thousands):
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2021 |
|
| 2020 |
|
| 2021 |
|
| 2020 |
| ||||
|
| (As Restated) |
|
| (As Restated) |
| ||||||||||
Net loss – basic |
| $ | (12,156 | ) |
| $ | (8,026 | ) |
| $ | (29,666 | ) |
| $ | (7,314 | ) |
Change in fair value of warrant liability |
|
| (5,458 | ) |
|
| (7,083 | ) |
|
| (8,046 | ) |
|
| (20,307 | ) |
Net loss – diluted |
| $ | (17,614 | ) |
| $ | (15,109 | ) |
| $ | (37,712 | ) |
| $ | (27,621 | ) |
Share used in calculating net loss per share was determined as follows (in thousands):
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2021 |
|
| 2020 |
|
| 2021 |
|
| 2020 |
| ||||
Weighted average shares used in calculating basic net loss per share |
|
| 126,725 |
|
|
| 112,524 |
|
|
| 115,982 |
|
|
| 112,480 |
|
Effect of potentially dilutive common shares from equity awards and liability-classified warrants |
|
| 1,435 |
|
|
| 1,937 |
|
|
| 2,675 |
|
|
| 2,229 |
|
Weighted average shares used in calculating diluted net loss per share |
|
| 128,160 |
|
|
| 114,461 |
|
|
| 118,657 |
|
|
| 114,709 |
|
Our potentially dilutive shares, which include outstanding stock options, restricted stock units, and warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.
The following table presents weighted-average potentially dilutive shares that have been excluded from the calculation of net loss per share because of their anti-dilutive effect (in thousands):
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2021 |
|
| 2020 |
|
| 2021 |
|
| 2020 |
| ||||
Stock options |
|
| 20,460 |
|
|
| 15,128 |
|
|
| 20,671 |
|
|
| 15,347 |
|
Restricted stock units |
|
| 229 |
|
|
| 430 |
|
|
| 244 |
|
|
| 430 |
|
Total anti-dilutive shares |
|
| 20,689 |
|
|
| 15,558 |
|
|
| 20,915 |
|
|
| 15,777 |
|
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever MEI Pharma makes a similar move, sign up!
